Volume 2.49 | Dec 13

Hematopoiesis News 2.49, December 13, 2011
Hematopoiesis News
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
TOP STORY
An Intrinsic BM Hematopoietic Niche Occupancy Defect of HSC in Scid Mice Facilitates Exogenous HSC Engraftment
Investigators hypothesized that the DNA repair defect of scid mice results in a stem cell defect that facilitates HSC engraftment. [Blood] Abstract


Try Our New STEMvision App!
PUBLICATIONS (Ranked by Impact Factor of the Journal)
LABORATORY RESEARCH

SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Researchers obtained DNA samples from leukemia cells in 91 patients with chronic lymphocytic leukemia and performed massively parallel sequencing of 88 whole exomes and whole genomes, together with sequencing of matched germline DNA, to characterize the spectrum of somatic mutations in this disease. [N Engl J Med] Abstract | Press Release

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia
Scientists show that imatinib, nilotinib, and dasatinib possess weak off-target activity against RAF and, therefore, drive paradoxical activation of BRAF and CRAF in a RAS-dependent manner. [Cancer Cell] Abstract | Press Release

Extramedullary Hematopoiesis Generates Ly-6CHigh Monocytes that Infiltrate Atherosclerotic Lesions
Using murine models of atherosclerosis and fate-mapping approaches, researchers show that hematopoietic stem and progenitor cells progressively relocate from the bone marrow to the splenic red pulp where they encounter GM-CSF and IL-3, clonally expand, and differentiate to Ly-6Chigh monocytes. [Circulation] Abstract


Erythrocyte Plasma Membrane-Bound ERK1/2 Activation Promotes ICAM-4-Mediated Sickle Red Cell Adhesion to Endothelium
Since erythrocytes (RBCs) contain abundant extracellular signal-regulated kinase-1/2 (ERK1/2), scientists predicted that ERK1/2 is functional in sickle RBCs and promotes adherence, a hallmark of sickle cell disease. [Blood] Abstract


KIT with D816 Mutations Cooperates with CBFB-MYH11 for Leukemogenesis in Mice
Here, researchers transduced wild type and conditional Cbfb-MYH11 knock-in mouse bone marrow cells with KIT D816V/Y mutations. [Blood] Abstract


A Small Molecule Screening Strategy with Validation on Human Leukemia Stem Cells Uncovers the Therapeutic Efficacy of Kinetin Riboside
Here, investigators present a multi-step in vitro and in vivo approach to identify compounds that can target leukemia-initiating cells in acute myeloid leukemia. [Blood] Abstract


Cut and Paste: Restoring Cellular Function by Gene Correction
By using a mouse model of sickle cell anemia, the authors were able to “edit” the genome of murine induced pluripotent stem cells, thereby allowing for the re-introduction of a wild-type version of the defective hemoglobin gene. [Cell Res] Abstract | Press Release

Runx1 Loss Minimally Impacts Long-Term Hematopoietic Stem Cells
Here researchers show that Runx1 deficiency decreases both apoptosis and proliferation, but only minimally impacts the frequency of long term repopulating hematopoietic stem cells. [PLoS One] Abstract


Identification of c-Myb Target Genes in K562 Cells Reveals a Role for c-Myb as a Master Regulator
The c-Myb transcription factor is an important regulator of hematopoietic cell development. Here, scientists report a set of novel c-Myb target genes, identified using a combined approach: specific c-Myb knockdown by 2 different siRNAs and subsequent global expression profiling, combined with the confirmation of direct binding of c-Myb to the target promoters by ChIP assays. [Genes Cancer] Abstract


A Novel Potent Fas Agonist for Selective Depletion of Tumor Cells in Hematopoietic Transplants
Here scientists propose the use of a novel Fas agonist with potent pro-apoptotic activity, termed MegaFasL, as an effective ex-vivo purging agent. [Blood Cancer J] Abstract


CLINICAL RESEARCH

ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin’s Lymphoma
Researchers randomly assigned 405 patients with previously untreated stage IA or IIA non-bulky Hodgkin’s lymphoma to treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone or to treatment with subtotal nodal radiation therapy, with or without ABVD therapy. [N Engl J Med]
Abstract | Press Release

Dasatinib or Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 2-Year Follow-Up from a Randomized Phase III Trial (DASISION)
In the Phase III DASISION trial, patients with newly diagnosed chronic-phase chronic myeloid leukemia were randomized to receive dasatinib 100 mg (n=259) or imatinib 400 mg (n=260) once daily. [Blood] Abstract


See Our Customized Services - In Vitro Assays To Assess Immunomodulation In Drug Development
SCIENCE NEWS
Studies Assess Hydroxyurea Therapy and Pre-Operative Transfusions for Patients with Sickle Cell Disease
Research assessing the safety and efficacy of hydroxyurea therapy in pediatric patients with sickle cell disease (SCD) and the use of pre-operative transfusions for patients with SCD who undergo low- and moderate-risk elective surgery was presented. [Press release from the American Society of Hematology discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release


Studies Investigate New Methodologies to Improve Recovery and Survival Strategies for Patients Undergoing Hematopoietic Cell Transplantation
Hematopoietic cell transplantation is the primary option for treatment for many patients who suffer from various hematologic disorders. The studies presented demonstrate the major advances underway in the field of hematopoietic cell transplantation. [Press release from the American Society of Hematology discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release


Genetic and Proteomic Advances Pave the Way for Next-Generation Leukemia Therapies
New research addressing important updates on the diagnosis and treatment of leukemia was presented. [Press release from the American Society of Hematology discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release


Stem Cells Used to Produce Blood Platelets
Scientists have, for the first time, created blood platelet cells by reprogramming stem cells derived from adult cells, offering the potential for a renewable supply of the fragile blood component. [Press release from Reuters discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release


Pfizer’s Failed Blood Cancer Drug Shows New Benefits in Study
Pfizer Inc.’s blood-cancer drug Mylotarg, pulled from the market last year after it was linked to deaths, helped a different group of patients, a study found. [Press release from Bloomberg Businessweek discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release


Results from a Comparative Analysis Show REVLIMID® Demonstrates Statistically Significant Reduction in Risk of Death and No Evidence of Increased Risk of Progression to AML in Patients with Deletion 5q MDS Compared with Best Supportive Care
Celgene International Sàrl announced results from a retrospective analysis to assess the risk of acute myeloid leukemia (AML) progression and death in REVLIMID® (lenalidomide)-treated versus untreated patients with red blood cell transfusion-dependent patients with IPSS Low or Int-1 risk myelodysplastic syndromes with deletion 5q chromosome. [Press release from Celgene International Sarl discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego]
Press Release


Celator® Pharmaceuticals and the Leukemia & Lymphoma Society® Announce Positive Data from Phase IIB Study of CPX-351
Celator Pharmaceuticals and The Leukemia & Lymphoma Society announced positive clinical data in first relapse patients with acute myeloid leukemia treated with CPX-351 (Cytarabine:Daunorubicin) Liposome Injection. [Press release from Celator® Pharmaceuticals discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release


Coronado Biosciences Announces Phase I Results of CNDO-109 in AML
Coronado Biosciences, Inc. announced that an oral presentation on CND0-109 was given. CNDO-109 is a biologic that activates natural killer cells for the treatment of acute myeloid leukemia (AML) and solid tumors. [Press release from Coronado Biosciences, Inc. discussing research presented at the 53rd Annual Meeting of the American Society of Hematology, San Diego] Press Release


Promising Prognostic and Preclinical Data for Acute Myeloid Leukemia and BerGenBio’s BGB324
The research, completed by Sonja Loges, M.D., Ph.D. from University of Hamburg, suggests that Axl is a useful prognostic indictor for Acute Myeloid Leukemia and that BerGenBio`s inhibitor, BGB324, is a highly effective therapeutic candidate. [Press release from BerGenBio AS discussing research presented at the 53rd Annual Meeting of the American Society of Hematology (ASH), San Diego] Press Release

Season's Greetings: Wishing You a Joyous Holiday Season and a Happy New Year
INDUSTRY NEWS
RemedyMD to Launch New Leukemia and Lymphoma Registries
RemedyMD launched the Mosaic Lymphoma™ and Mosaic Leukemia™ registries at the American Society of Hematology Annual Meeting and Exposition. [RemedyMD] Press Release


CIRM Approves $27 Million for Initiatives to Accelerate Promising Stem Cell Research Projects
The California Institute for Regenerative Medicine (CIRM) enhanced its efforts to proactively discover and fund innovative research and to provide continuous support to successful research programs, speeding the development of new stem cell-based therapies. [California Institute for Regenerative Medicine]
Press Release


£50 Million Technology and Innovation Center in Cell Therapy to Come to London
The new center will support the development and commercialization of cell therapies and advanced therapeutics, as well as the underpinning technologies for manufacturing, quality control, safety and efficiency. [Technology Strategy Board] Press Release
POLICY NEWS
Approval History, Letters, Reviews and Related Documents – Hemacord [Center for Biologics Evaluation and Research, United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS
NEW International Society for Stem Cell Research 10th Annual Meeting
June 13-16, 2012
Yokohama, Japan

Visit our events page 
to see a complete list of events in the hematopoietic community
JOB OPPORTUNITIES
Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Research Technologist, Manufacturing Sciences (STEMCELL Technologies)

Business Analyst – Product Management (STEMSOFT Software)

Postdoctoral Positions in Stem Cell Biology (Columbia University)

Professorship in Hematopoietic Stem Cell Transplantation and Head (University of Göttingen)


Marie Curie Experienced Researcher (Alexander Fleming Biomedical Sciences Research Center)

Postdoctoral Position – Center for Human Genetics (VIB Research Institute)

Postgraduate Students (Masaryk University)


Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us